Autoimmune Effect of Antibodies against the SARS-CoV-2 Nucleoprotein.
Daria MatyushkinaVarvara ShokinaPolina TikhonovaValentin ManuveraDmitry ShirokovDaria KharlampievaVasily LazarevAnna VarizhukTatiana VedekhinaAlexander PavlenkoLeonid PenkinGeorgij P ArapidiKonstantin V PavlovDmitry PushkarKonstantin KolontarevAlexander RumyantsevSergey RumyantsevLyubov RychkovaVadim GovorunPublished in: Viruses (2022)
COVID-19 caused by SARS-CoV-2 is continuing to spread around the world and drastically affect our daily life. New strains appear, and the severity of the course of the disease itself seems to be decreasing, but even people who have been ill on an outpatient basis suffer post-COVID consequences. Partly, it is associated with the autoimmune reactions, so debates about the development of new vaccines and the need for vaccination/revaccination continue. In this study we performed an analysis of the antibody response of patients with COVID-19 to linear and conformational epitopes of viral proteins using ELISA, chip array and western blot with analysis of correlations between antibody titer, disease severity, and complications. We have shown that the presence of IgG antibodies to the nucleoprotein can deteriorate the course of the disease, induce multiple direct COVID-19 symptoms, and contribute to long-term post-covid symptoms. We analyzed the cross reactivity of antibodies to SARS-CoV-2 with own human proteins and showed that antibodies to the nucleocapsid protein can bind to human proteins. In accordance with the possibility of HLA presentation, the main possible targets of the autoantibodies were identified. People with HLA alleles A01:01; A26:01; B39:01; B15:01 are most susceptible to the development of autoimmune processes after COVID-19.